KOREA WHO

Choi Young-ho is the CEO of Access Bio.

He aims to transform the company from a diagnostic kit specialist into a comprehensive healthcare enterprise.

He was born on January 8, 1964.

Choi earned a degree in Agricultural Chemistry from Korea University and a master’s degree in Biotechnology from KAIST (Korea Advanced Institute of Science and Technology).

He began his career at the CJ CheilJedang Central Research Institute, later joining Princeton BioMeditech (PBM) in the United States, where he eventually became head of research.

In 2002, he founded Access Bio in the U.S. He also established a subsidiary, Wells Bio, and a private company, Medisensor, becoming chairman and CEO of both.

In 2019, he sold his stake and management rights in Access Bio to PharmGen Science (formerly Wooridul Pharmaceutical) for KRW 30 billion (US$ 21.6 million), continuing to lead the company as a professional executive.

Founded in the U.S. by a Korean entrepreneur, Access Bio became the first U.S.-based biotech firm to be listed on KOSDAQ.

With over 30 years of research experience in diagnostic kits, Choi led the company to become the global leader in malaria diagnostics.

#AccessBio #ChoiYoungho #diagnostickits #healthcare #biotech #KOSDAQ #malariadiagnostics #KAIST #PharmGenScience #WellsBio